Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1

Particle and Fibre Toxicology

Meng Wang¹  Hong Yin¹  Delin Zhang¹  Guangxiang Wang¹  Yanhua Wang¹ 

[1] Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, China

关键词: Pig antibodies;    Epitope;    SAG1;    Toxoplasma gondii;   

Others  :  1227975
DOI  :  10.1186/1756-3305-6-125

 received in 2013-01-04, accepted in 2013-04-26,  发布年份 2013

【 摘 要 】

Background

The identification of protein epitopes is useful for diagnostic purposes and for the development of peptide vaccines. In this study, the epitopes of Toxoplasma gondii SAG1 were identified using synthetic peptide techniques with the aid of bioinformatics.

Findings

Eleven peptides derived from T. gondii SAG1 were assessed by ELISA using pig sera from different time points after infection. Four (PS4, PS6, PS10 and PS11), out of the eleven peptides tested were recognized by all sera. Then, shorter peptides that were derived from PS4, PS6, PS10 and PS11 were predicted using bioinformatics and tested by experimentation. Four out of nine shorter peptides were identified successfully (amino acids 106–120, 166–180, 289–300 and 313–332).

Conclusions

We have precisely located the epitopes of T. gondii SAG1 using pig sera collected at different time points after infection. The identified epitopes may be useful for the further study of epitope-based vaccines and diagnostic reagents.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Nardoni S, Angelici M, Mugnaini L, Mancianti F: Prevalence of Toxoplasma gondii infection in Myocastor coypus in a protected Italian wetland. Parasites Vectors 2011, 4:240. BioMed Central Full Text
• [2]Zhou P, Chen Z, Li HL, Zheng H, He S, Lin RQ, Zhu XQ: Toxoplasma gondii infection in humans in China. Parasit Vectors 2011, 4:165. BioMed Central Full Text
• [3]Boughattas S, Bergaoui R, Essid R, Aoun K, Bouratbine A: Seroprevalence of Toxoplasma gondii infection among horses in Tunisia. Parasites Vectors 2011, 4:218. BioMed Central Full Text
• [4]Yang N, Mu MY, Li HK, Long M, He JB: Seroprevalence of Toxoplasma gondii infection in slaughtered chickens, ducks, and geese in Shenyang, northeastern China. Parasites Vectors 2012, 5:237. BioMed Central Full Text
• [5]Wang M, Wang YH, Ye Q, Meng P, Yin H, Zhang DL: Serological survey of Toxoplasma gondii in Tibetan mastiffs (Canislupus familiaris) and yaks (Bos grunniens) in Qinghai, China. Parasites Vectors 2012, 5:35. BioMed Central Full Text
• [6]Sun XS, Zou J, Elashram Saeed AA, Yan WC, Liu XY, Suo X, Wang H, Chen QJ: DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice. Parasites Vectors 2011, 4:213. BioMed Central Full Text
• [7]Wang YH, Wang M, Wang GX, Pang AN, Fu BQ, Yin H, Zhang DL: Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens. Vaccine 2011, 29:8619-8623.
• [8]Velge-Roussel F, Chardès T, Mévélec P, Brillard M, Hoebeke J, Bout D: Epitopic analysis of the Toxoplasma gondii major surface antigen SAG1. Mol Biochem Parasitol 1994, 66:31-38.
• [9]Siachoque H, Guzman F, Burgos J, Patarroyo ME, Marin JEG: Toxoplasma gondii: Immunogenicity and protection by P30 peptides in a murine model. Exp Parasitol 2006, 114:62-65.
• [10]Cardona N, de-la-Torre A, Siachoque H, Patarroyo MA, Gomez-Marin JE: Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis. Exp Parasitol 2009, 123:199-202.
• [11]Jalallou N, Bandepour M, Khazan H, Haghighi A, Abdollahi SH, Kazemi B: Recombinant SAG1 antigen to detect Toxoplasma gondii specific immunoglobulin G in human sera by ELISA test. Iranian J Parasitol 2010, 5:1-9.
• [12]Zhang ZW, Zhang YG, Wang YL, Pan L, Fang YZ, Jiang ST, Lu JL, Zhou P: Screening and identification of B cell epitopes of structural proteins of foot-and-mouth disease virus serotype Asia I. Vet Microbiol 2010, 140:25-33.